Article in Frontiers in genetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
4 authors.
Luca ErminiNORLUX NeuroOncology Laboratory, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg.
Diego MalloArizona Cancer Evolution Center, Biodesign Institute and School of Life Sciences, Arizona State University, Tempe, AZ, United States.
Dimitrios KleftogiannisDepartment of Informatics, Computational Biology Unit and Centre for Cancer Biomarkers, University of Bergen, Bergen, Norway.
Ahmet AcarDepartment of Biological Sciences, Middle East Technical University, Universiteler Mah, Ankara, Turkiye.
Funding
Molecular, Cellular and Tissue Characterization UnitU2CCA233254 · NCI · DUKE UNIVERSITY · PI HWANG, E.SHELLEY · 2018 to 2023
$11.4M
The Role of the Microbiome in Cancer Suppression and Susceptibility Across SpeciesU54CA217376 · NCI · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI MALEY, CARLO · 2018 to 2022
$8.6M
Modeling Neoplastic Progression in Barrett's Esophagus - Renewal -2R01CA140657 · NCI · WISTAR INSTITUTE · PI Carlo Maley · 2009 to 2026
$5.0M
A cell-cycle induced genetic recorder for simultaneous recovery of cell divisions and lineageR21CA257980 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI MALEY, CARLO, WEISS, RON · 2022 to 2023
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Editorial: Cancer evolution. · full record | OpenQuestion